



## KEY DATA

Stock country	Sweden
Bloomberg	ORX SS
Reuters	ORX.ST
Share price (close)	SEK 64.00
Free Float	89%
Market cap. (bn)	EUR 0.21/SEK 2.31
Website	www.orexo.com
Next report date	16 Jul 2020

## PERFORMANCE



## VALUATION APPROACH



## ESTIMATE CHANGES

Year	2020E	2021E	2022E
Sales	-5%	-1%	-2%
EBIT (adj)	-3%	-2%	-4%

Source: Nordea estimates

## Nordea Markets - Analysts

Klas Pyk  
Analyst

## Favourable market for a digital launch

Orexo yet again proved that Zubsolv is resilient against the recent entry of generic competition. We argue, however, that investors should look at the potential from the upcoming launch of the digital therapeutic offering, planned for Q3 2020 at the latest – particularly since the COVID-19 outbreak has increased demand for digital healthcare solutions.

## We expect Zubsolv to remain resilient in 2020

Total revenues were SEK 175.0m in the quarter, compared to SEK 174.3m for the same period last year. Orexo's flagship product Zubsolv booked sales of SEK 163.9m, compared to our estimate of SEK 162.9m, corresponding to a decline of 4.0% y/y in local currency. In its report, the company reiterated its outlook for flat sales for Zubsolv in 2020 (based on December FX rates). Even though we expect lower volumes throughout the year, we argue that sales will stand resilient against the recent entry of generic competition, thanks to a shift towards more profitable segments, and we forecast sales of SEK 739.0m in 2020, corresponding to a decline of 2.5% y/y in local currency. EBITDA in the quarter was SEK 39.1m, well ahead of our forecast of SEK 17.4m, driven by a better-than-expected gross margin and a one-off positive impact of SEK 10.1m.

## COVID-19 could open up for an accelerated launch of vorvida

In our view, the main factor to consider when investing in Orexo is the company's pipeline potential, particularly in digital therapeutics. The first digital product for alcohol abuse, vorvida, is planned for launch in Q3 2020 at the latest and has sales potential of USD 120-200m, according to the company. We argue that the COVID-19 outbreak has increased the demand for digital healthcare solutions, as confirmed by the company's ambition for an accelerated launch, eg during Q2.

## All eyes on the upcoming launch

Despite the better-than-expected report, we lower our sales and EBIT forecasts for 2020-22, largely owing to timing effects for RoW Zubsolv. In our view, the upcoming launch of vorvida will represent the next trigger for the share, alongside any additional pipeline news flow. We make no major changes to our estimates following the Q1 report and reiterate our DCF-based valuation range of SEK 72-82 per share.

## SUMMARY TABLE - KEY FIGURES

SEKm	2016	2017	2018	2019	2020E	2021E	2022E
Total revenue	706	644	783	845	797	866	902
EBITDA (adj)	74	78	117	224	173	242	268
EBIT (adj)	52	57	96	183	146	214	239
EBIT (adj) margin	7.3%	8.9%	12.2%	21.6%	18.4%	24.7%	26.5%
EPS (adj)	0.84	0.67	3.92	4.82	5.41	5.61	5.95
EPS (adj) growth	114.7%	-20.5%	485.5%	23.0%	12.2%	3.6%	6.2%
DPS (ord)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EV/Sales	2.0	2.2	2.3	2.1	2.1	1.7	1.3
EV/EBIT (adj)	27.4	24.7	18.8	9.6	11.2	6.7	5.1
P/E (adj)	44.7	61.6	15.0	13.0	11.8	11.4	10.8
P/BV	4.2	4.3	4.4	3.1	2.5	2.1	1.7
Dividend yield (ord)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield bef A&D, lease	5.0%	4.3%	11.7%	13.1%	7.9%	9.9%	11.2%
Net debt	115	-9	-269	-473	-628	-830	-1,045
Net debt/EBITDA	1.6	-0.1	-2.3	-2.1	-3.6	-3.4	-3.9
ROIC after tax	6.4%	8.1%	15.0%	29.1%	22.1%	31.1%	34.0%

Source: Company data and Nordea estimates

# Estimate revisions

## OREXO: DETAILED ESTIMATES

	New estimates			Old estimates			Diff. %		
	2020E	2021E	2022E	2020E	2021E	2022E	2020E	2021E	2022E
<b>Net revenues</b>	<b>796.9</b>	<b>866.0</b>	<b>902.5</b>	<b>836.9</b>	<b>871.9</b>	<b>922.2</b>	<b>-5%</b>	<b>-1%</b>	<b>-2%</b>
<b>Gross profit</b>	704.4	766.4	798.7	723.9	758.6	802.3	<b>-3%</b>	<b>1%</b>	<b>0%</b>
Gross margin, %	88.4%	88.5%	88.5%	86.5%	87.0%	87.0%	1.9pp	1.5pp	1.5pp
<b>EBITDA</b>	<b>173.0</b>	<b>242.0</b>	<b>267.7</b>	<b>177.2</b>	<b>246.1</b>	<b>277.5</b>	<b>-2%</b>	<b>-2%</b>	<b>-4%</b>
EBITDA margin, %	22%	28%	30%	21%	28%	30%	0.5pp	-0.3pp	-0.4pp
NRI	0	0	0	0	0	0	nm.	nm.	nm.
<b>Adj. EBITDA</b>	<b>173.0</b>	<b>242.0</b>	<b>267.7</b>	<b>177.2</b>	<b>246.1</b>	<b>277.5</b>	<b>-2%</b>	<b>-2%</b>	<b>-4%</b>
Adj. EBITDA margin, %	18.4%	24.7%	26.5%	18.0%	25.0%	27.0%	0.4pp	-0.3pp	-0.5pp
<b>EBIT</b>	<b>146.4</b>	<b>213.9</b>	<b>239.2</b>	<b>150.6</b>	<b>218.0</b>	<b>249.0</b>	<b>-3%</b>	<b>-2%</b>	<b>-4%</b>
EBIT margin, %	18.4%	24.7%	26.5%	18.0%	25.0%	27.0%	0.4pp	-0.3pp	-0.5pp

Source: Company data and Nordea estimates

# Detailed estimates

## OREXO: DETAILED ESTIMATES

SEKm	2019				2020				2019	2020E	2021E	2022E
	Q1	Q2	Q3	Q4	Q1E	Q2E	Q3E	Q4E				
<b>Net sales</b>	<b>174</b>	<b>201</b>	<b>231</b>	<b>238</b>	<b>175</b>	<b>196</b>	<b>199</b>	<b>226</b>	<b>845</b>	<b>797</b>	<b>866</b>	<b>902</b>
- whereof Zubsolov US	162	184	183	191	164	190	191	194	719	739	767	780
Gross profit	149	170	205	215	155	175	176	199	739	704	766	799
Gross, margin	85.5%	84.4%	88.8%	90.3%	88.6%	89.0%	88.0%	88.0%	87.5%	88.4%	88.5%	88.5%
EBITDA	-37	60	114	86	39	40	38	56	224	173	242	268
EBITDA margin, %	-21.1%	30.0%	49.4%	36.1%	22.3%	20.4%	18.9%	24.9%	26.5%	21.7%	27.9%	29.7%
IP litigation costs	49	3	-3	1	0	0	0	0	50	0	0	0
<b>Adjusted EBITDA</b>	<b>12</b>	<b>64</b>	<b>111</b>	<b>87</b>	<b>39</b>	<b>40</b>	<b>38</b>	<b>56</b>	<b>273</b>	<b>173</b>	<b>242</b>	<b>268</b>
Adjusted EBITDA margin, %	6.9%	31.6%	48.1%	36.3%	22.4%	20.4%	18.9%	24.9%	32.3%	21.7%	27.9%	29.7%
<b>EBIT</b>	<b>-48</b>	<b>53</b>	<b>106</b>	<b>72</b>	<b>34</b>	<b>33</b>	<b>31</b>	<b>48</b>	<b>183</b>	<b>146</b>	<b>214</b>	<b>239</b>
EBIT margin	-27.4%	26.2%	45.8%	30.1%	19.4%	17.0%	15.5%	21.3%	21.6%	18.4%	24.7%	26.5%
Net income	-35	55	112	39	83	32	30	46	171	191	198	210

Source: Company data and Nordea estimates

# Valuation

We derive a DCF-based fair value range of SEK 72-82, using a WACC of 8-10%

In our DCF model, we use our explicit forecast for Orexo until 2025, plus a set of general assumptions until 2050, as outlined below. The DCF model uses a stringent approach, with ROIC equalling WACC in the terminal year, preventing the model from extrapolating above-market returns in perpetuity.

## OREXO: DCF ASSUMPTIONS

	2020-25	2026-30	2031-35	2036-40	2041-45	2046-50	Sust.
Sales growth, CAGR	3.3%	4.0%	3.0%	2.5%	2.5%	2.5%	
EBIT-margin, excluding associates	27.8%	16.5%	14.0%	14.0%	14.0%	5.2%	
Capex/depreciation, x	0.9	1.0	1.0	1.0	1.0	1.0	
Capex/sales	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	
NWC/sales	28.1%	30.0%	30.0%	30.0%	30.0%	30.0%	
FCFF, CAGR	17.1%	-9.6%	0.1%	2.9%	2.5%	-20.0%	2.5%

Source: Nordea estimates

## DCF MODEL SENSITIVITY, SALES GROWTH, AND EBIT MARGIN CHANGE

		Sales growth change				
		-1.0pp	-0.5pp		+0.5pp	+1.0pp
EBIT margin change	+1.0pp	77	78	78	79	80
	+0.5pp	76	77	77	78	79
		75	76	76	77	78
	-0.5pp	74	75	75	76	77
	-1.0pp	73	74	74	75	76

Source: Company data and Nordea estimates

## DCF MODEL SENSITIVITY, WACC, AND SALES GROWTH CHANGE

		WACC				
		8.0%	8.5%	9.0%	9.5%	10.0%
Sales growth change	+1.0pp	85	81	78	75	73
	+0.5pp	83	80	77	75	72
		82	79	76	74	72
	-0.5pp	81	78	76	73	71
	-1.0pp	80	77	75	73	70

Source: Company data and Nordea estimates


## DCF MODEL SENSITIVITY, WACC, AND EBIT MARGIN CHANGE

		WACC				
		8.0%	8.5%	9.0%	9.5%	10.0%
EBIT margin change	+1.0pp	85	82	78	76	73
	+0.5pp	84	80	77	75	72
		82	79	76	74	72
	-0.5pp	81	78	75	73	71
	-1.0pp	80	77	74	72	70

Source: Company data and Nordea estimates


At NTM adjusted P/E of 17x and NTM adjusted EV/EBIT of 14x, Orexo trades in line with its historical average.

**OREXO: NTM P/E**



Source: Thomson Reuters

**OREXO: NTM EV/EBIT**



Source: Thomson Reuters

# Reported numbers and forecasts

## INCOME STATEMENT

SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
<b>Total revenue</b>	<b>326</b>	<b>429</b>	<b>570</b>	<b>643</b>	<b>706</b>	<b>644</b>	<b>783</b>	<b>845</b>	<b>797</b>	<b>866</b>	<b>902</b>
Revenue growth	63.5%	31.6%	32.8%	12.8%	9.7%	-8.8%	21.7%	7.9%	-5.7%	8.7%	4.2%
of which organic	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
of which FX	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBITDA	-62	-90	-12	-150	74	78	117	224	173	242	268
Depreciation and impairments PPE	-6	-5	-5	-4	-5	-4	-4	-8	-21	-20	-17
of which leased assets	0	0	0	0	0	0	0	0	0	0	0
EBITA	-68	-94	-17	-154	70	74	112	215	152	222	251
Amortisation and impairments	-11	-46	-8	-15	-18	-17	-17	-33	-5	-8	-11
EBIT	-79	-140	-25	-169	52	57	96	183	146	214	239
of which associates	0	0	0	0	0	0	0	0	0	0	0
Associates excluded from EBIT	0	0	0	0	0	0	0	0	0	0	0
Net financials	-8	-14	-28	-22	-16	-28	-4	-3	51	6	8
of which lease interest	0	0	0	0	0	0	0	0	0	0	0
Changes in value, net	0	0	0	0	0	0	0	0	0	0	0
<b>Pre-tax profit</b>	<b>-88</b>	<b>-153</b>	<b>-53</b>	<b>-191</b>	<b>36</b>	<b>30</b>	<b>92</b>	<b>179</b>	<b>197</b>	<b>220</b>	<b>247</b>
Reported taxes	2	-2	-4	-7	-7	-7	46	-9	-6	-22	-37
Net profit from continued operations	-86	-155	-57	-198	29	23	138	171	191	198	210
Discontinued operations	0	0	0	0	0	0	0	0	0	0	0
Minority interests	0	0	0	0	0	0	0	0	0	0	0
Net profit to equity	-86	-155	-57	-198	29	23	138	171	191	198	210
<b>EPS</b>	<b>-2.98</b>	<b>-4.87</b>	<b>-1.73</b>	<b>-5.74</b>	<b>0.84</b>	<b>0.67</b>	<b>3.92</b>	<b>4.82</b>	<b>5.41</b>	<b>5.61</b>	<b>5.95</b>
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which ordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit margin in percent</b>											
EBITDA	-19.0%	-20.9%	-2.2%	-23.4%	10.5%	12.1%	14.9%	26.5%	21.7%	27.9%	29.7%
EBITA	-21.0%	-21.9%	-3.1%	-24.0%	9.9%	11.5%	14.4%	25.5%	19.0%	25.7%	27.8%
EBIT	-24.3%	-32.5%	-4.4%	-26.2%	7.3%	8.9%	12.2%	21.6%	18.4%	24.7%	26.5%

## Adjusted earnings

EBITDA (adj)	-62	-90	-12	-150	74	78	117	224	173	242	268
EBITA (adj)	-68	-94	-17	-154	70	74	112	215	152	222	251
EBIT (adj)	-79	-140	-25	-169	52	57	96	183	146	214	239
EPS (adj)	-2.98	-4.87	-1.73	-5.74	0.84	0.67	3.92	4.82	5.41	5.61	5.95

## Adjusted profit margins in percent

EBITDA (adj)	-19.0%	-20.9%	-2.2%	-23.4%	10.5%	12.1%	14.9%	26.5%	21.7%	27.9%	29.7%
EBITA (adj)	-21.0%	-21.9%	-3.1%	-24.0%	9.9%	11.5%	14.4%	25.5%	19.0%	25.7%	27.8%
EBIT (adj)	-24.3%	-32.5%	-4.4%	-26.2%	7.3%	8.9%	12.2%	21.6%	18.4%	24.7%	26.5%

## Performance metrics

CAGR last 5 years											
Net revenue	n.a.	n.a.	n.a.	n.a.	28.7%	14.6%	12.8%	8.2%	4.4%	4.2%	7.0%
EBITDA	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	26.6%	27.9%
EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	32.8%	33.0%
EPS	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	46.1%	54.8%
DPS	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Average last 5 years											
Average EBIT margin	n.a.	n.a.	n.a.	n.a.	-13.5%	-7.5%	0.3%	6.0%	14.1%	17.7%	20.9%
Average EBITDA margin	n.a.	n.a.	n.a.	-14.5%	-9.0%	-3.3%	3.2%	9.5%	17.6%	21.2%	24.4%

## VALUATION RATIOS - ADJUSTED EARNINGS

SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
P/E (adj)	n.m.	n.m.	n.m.	n.m.	44.7	61.6	15.0	13.0	11.8	11.4	10.8
EV/EBITDA (adj)	n.m.	n.m.	n.m.	n.m.	19.0	18.2	15.5	7.8	9.4	5.9	4.5
EV/EBITA (adj)	n.m.	n.m.	n.m.	n.m.	20.3	19.2	16.0	8.1	10.8	6.4	4.9
EV/EBIT (adj)	n.m.	n.m.	n.m.	n.m.	27.4	24.7	18.8	9.6	11.2	6.7	5.1

## VALUATION RATIOS - REPORTED EARNINGS

SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
P/E	n.m.	n.m.	n.m.	n.m.	44.7	61.6	15.0	13.0	11.8	11.4	10.8
EV/Sales	4.05	12.46	8.14	3.82	2.01	2.21	2.30	2.07	2.05	1.65	1.35
EV/EBITDA	n.m.	n.m.	n.m.	n.m.	19.0	18.2	15.5	7.8	9.4	5.9	4.5
EV/EBITA	n.m.	n.m.	n.m.	n.m.	20.3	19.2	16.0	8.1	10.8	6.4	4.9
EV/EBIT	n.m.	n.m.	n.m.	n.m.	27.4	24.7	18.8	9.6	11.2	6.7	5.1
Dividend yield (ord.)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF yield	2.4%	-2.3%	4.1%	-4.1%	5.5%	4.2%	11.4%	11.9%	7.9%	9.9%	11.2%
FCF Yield bef A&D, lease adj	1.9%	-0.2%	5.7%	-4.9%	5.0%	4.3%	11.7%	13.1%	7.9%	9.9%	11.2%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Company data and Nordea estimates

**BALANCE SHEET**

SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
Intangible assets	135	195	259	155	138	121	104	114	117	116	113
of which R&D	106	164	224	147	132	117	100	100	103	102	99
of which other intangibles	3	4	7	8	6	5	4	14	14	14	14
of which goodwill	26	26	27	0	0	0	0	0	0	0	0
Tangible assets	35	33	29	25	22	20	20	79	98	98	98
of which leased assets	0	0	0	0	0	0	0	57	76	76	76
Shares associates	0	0	0	0	0	0	0	0	0	0	0
Interest bearing assets	0	0	0	0	0	0	0	0	0	0	0
Deferred tax assets	0	0	3	18	25	28	93	86	95	95	95
Other non-IB non-current assets	19	0	1	2	8	7	10	0	0	0	0
Other non-current assets	0	0	0	0	0	0	0	1	2	0	0
Total non-current assets	189	228	293	200	193	177	227	280	311	309	306
Inventory	28	383	488	403	344	250	174	132	127	139	144
Accounts receivable	18	36	142	168	179	218	296	273	257	279	291
Short-term leased assets	0	0	0	0	0	0	0	0	0	0	0
Other current assets	19	19	32	51	21	31	0	0	0	0	0
Cash and bank	228	106	285	198	282	328	590	817	951	1,154	1,369
Total current assets	293	544	946	820	826	827	1,060	1,221	1,335	1,572	1,804
Assets held for sale	0	0	0	0	0	0	0	0	0	0	0
<b>Total assets</b>	<b>482</b>	<b>772</b>	<b>1,239</b>	<b>1,020</b>	<b>1,019</b>	<b>1,004</b>	<b>1,287</b>	<b>1,501</b>	<b>1,646</b>	<b>1,881</b>	<b>2,110</b>
Shareholders equity	191	161	468	270	310	329	476	706	898	1,096	1,306
Of which preferred stocks	0	0	0	0	0	0	0	0	0	0	0
Of which equity part of hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Minority interest	0	0	0	0	0	0	0	0	0	0	0
Total Equity	191	161	468	270	310	329	476	706	898	1,096	1,306
Deferred tax	0	0	0	0	0	0	0	0	0	0	0
Long term interest bearing debt	118	104	494	494	398	319	321	290	250	250	250
Pension provisions	0	0	0	0	0	0	0	0	0	0	0
Other long-term provisions	4	10	9	7	1	6	7	11	11	11	11
Other long-term liabilities	0	0	0	0	0	0	0	0	0	0	0
Non-current lease debt	0	0	0	0	0	0	0	33	52	52	52
Convertible debt	0	0	0	0	0	0	0	0	0	0	0
Shareholder debt	0	0	0	0	0	0	0	0	0	0	0
Hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Total non-current liabilities	122	114	503	501	399	325	327	334	313	313	313
Short-term provisions	0	0	0	122	164	201	266	269	254	276	288
Accounts payable	20	138	29	35	36	46	0	0	0	0	0
Current lease debt	0	0	0	0	0	0	0	21	21	21	21
Other current liabilities	149	359	239	92	110	104	218	171	161	175	182
Short term interest bearing debt	0	0	0	0	0	0	0	0	0	0	0
Total current liabilities	169	497	268	249	310	350	483	461	436	472	491
Liabilities for assets held for sale	0	0	0	0	0	0	0	0	0	0	0
<b>Total liabilities and equity</b>	<b>482</b>	<b>772</b>	<b>1,239</b>	<b>1,020</b>	<b>1,019</b>	<b>1,004</b>	<b>1,287</b>	<b>1,501</b>	<b>1,646</b>	<b>1,881</b>	<b>2,110</b>
<b>Balance sheet and debt metrics</b>											
Net debt	-108	136	212	296	115	-9	-269	-473	-628	-830	-1,045
of which lease debt	0	0	0	0	0	0	0	55	74	74	74
Working capital	-104	-59	394	495	398	351	252	234	224	243	253
Invested capital	85	169	686	695	591	527	479	514	535	552	559
Capital employed	309	266	962	765	708	648	797	1,051	1,221	1,419	1,629
ROE	-89.8%	-87.9%	-18.0%	-53.6%	10.0%	7.3%	34.3%	28.8%	23.8%	19.9%	17.5%
ROIC	n.m.	-86.8%	-4.6%	-19.3%	6.4%	8.1%	15.0%	29.1%	22.1%	31.1%	34.0%
ROCE	-48.7%	-48.3%	-4.0%	-19.6%	7.0%	8.5%	13.3%	19.8%	12.9%	16.2%	15.7%
Net debt/EBITDA	n.m.	n.m.	n.m.	n.m.	1.6	-0.1	-2.3	-2.1	-3.6	-3.4	-3.9
Interest coverage	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Equity ratio	39.7%	20.9%	37.8%	26.5%	30.5%	32.8%	37.0%	47.1%	54.5%	58.3%	61.9%
Net gearing	-56.2%	83.9%	45.2%	109.7%	37.2%	-2.7%	-56.5%	-66.9%	-69.9%	-75.8%	-80.0%

Source: Company data and Nordea estimates

**CASH FLOW STATEMENT**

SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
<b>EBITDA (adj) for associates</b>	<b>-62</b>	<b>-90</b>	<b>-12</b>	<b>-150</b>	<b>74</b>	<b>78</b>	<b>117</b>	<b>224</b>	<b>173</b>	<b>242</b>	<b>268</b>
Paid taxes	0	-2	-4	0	0	0	0	0	0	0	0
Net financials	-8	-11	-28	-25	-28	-35	-32	-8	51	6	8
Change in provisions	4	6	-1	119	37	42	66	8	-15	22	12
Change in other LT non-IB	-19	19	-4	-16	-13	-3	-68	16	-10	2	0
Cash flow to/from associates	-53	0	0	0	0	0	0	0	0	0	0
Dividends paid to minorities	0	0	0	0	0	0	0	0	0	0	0
Other adj to reconcile to cash flow	77	16	13	25	-3	28	43	13	0	0	0
<b>Funds from operations (FFO)</b>	<b>-61</b>	<b>-62</b>	<b>-36</b>	<b>-47</b>	<b>68</b>	<b>110</b>	<b>125</b>	<b>253</b>	<b>199</b>	<b>272</b>	<b>288</b>
Change in NWC	90	-201	-452	-62	89	36	117	38	10	-19	-10
<b>Cash flow from operations (CFO)</b>	<b>29</b>	<b>-263</b>	<b>-487</b>	<b>-109</b>	<b>156</b>	<b>147</b>	<b>242</b>	<b>291</b>	<b>209</b>	<b>252</b>	<b>277</b>
Capital expenditure	-2	251	739	3	-91	-85	0	0	-29	-28	-25
<b>Free cash flow before A&amp;D</b>	<b>27</b>	<b>-12</b>	<b>252</b>	<b>-107</b>	<b>66</b>	<b>61</b>	<b>242</b>	<b>291</b>	<b>180</b>	<b>225</b>	<b>252</b>
Proceeds from sale of assets	13	0	0	22	7	0	0	10	0	0	0
Acquisitions	-6	-108	-72	-4	-1	-2	-6	-36	0	0	0
Free cash flow	34	-120	180	-89	71	60	236	265	180	225	252
Free cash flow bef A&D, lease adj	27	-12	252	-107	66	61	242	291	180	225	252
Dividends paid	0	0	0	0	0	0	0	0	0	0	0
Equity issues / buybacks	-52	19	342	4	2	0	0	2	0	0	0
Net change in debt	0	0	0	0	0	0	0	-56	-40	0	0
Other financing adjustments	0	0	0	0	0	0	0	0	-6	-22	-37
Other non-cash adjustments	246	-22	-343	-1	11	-14	26	16	0	0	0
Change in cash	228	-123	179	-86	84	46	262	227	134	203	215
<b>Cash flow metrics</b>											
Capex/D&A	8.7%	n.m.	n.m.	-14.1%	n.m.	n.m.	0.0%	0.0%	n.m.	98.5%	88.1%
Capex/Sales	0.5%	-58.5%	n.m.	-0.4%	12.8%	13.3%	0.0%	0.0%	3.7%	3.2%	2.8%
<b>Key information</b>											
Share price year end (/current)	50	164	136	63	38	41	59	63	64	64	64
Market cap.	1,430	5,214	4,431	2,164	1,300	1,428	2,071	2,221	2,262	2,262	2,262
Enterprise value	1,322	5,349	4,643	2,460	1,415	1,420	1,802	1,749	1,634	1,431	1,216
Diluted no. of shares, year-end (m)	28.8	31.8	32.7	34.5	34.6	34.7	35.2	35.4	35.3	35.3	35.3

Source: Company data and Nordea estimates



# Disclaimer and legal disclosures

## Origin of the report

This publication or report originates from: Nordea Bank Abp, including its branches Nordea Danmark, Filial af Nordea Bank Abp, Finland, Nordea Bank Abp, filial i Norge and Nordea Bank Abp, filial i Sverige (together "Nordea") acting through their unit Nordea Markets.

Nordea Bank Abp is supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the branches are supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the Financial Supervisory Authorities in their respective countries.

## Content of report

This report has been prepared solely by Nordea Markets.

Opinions or suggestions from Nordea Markets credit and equity research may deviate from one another or from opinions presented by other departments in Nordea. This may typically be the result of differing time horizons, methodologies, contexts or other factors.

The information provided herein is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information contained herein has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision.

Opinions or ratings are based on one or more methods of valuation, for instance cash flow analysis, use of multiples, behavioural technical analyses of underlying market movements in combination with considerations of the market situation and the time horizon. Key assumptions of forecasts or ratings in research cited or reproduced appear in the research material from the named sources. The date of publication appears from the research material cited or reproduced. Opinions and estimates may be updated in subsequent versions of the report, provided that the relevant company/issuer is treated anew in such later versions of the report.

## Validity of the report

All opinions and estimates in this report are, regardless of source, given in good faith, and may only be valid as of the stated date of this report and are subject to change without notice.

## No individual investment or tax advice

The report is intended only to provide general and preliminary information to investors and shall not be construed as the basis for any investment decision. This report has been prepared by Nordea Markets as general information for private use of investors to whom the report has been distributed, but it is not intended as a personal recommendation of particular financial instruments or strategies and thus it does not provide individually tailored investment advice, and does not take into account the individual investor's particular financial situation, existing holdings or liabilities, investment knowledge and experience, investment objective and horizon or risk profile and preferences. The investor must particularly ensure the suitability of an investment as regards his/her financial and fiscal situation and investment objectives. The investor bears the risk of losses in connection with an investment.

Before acting on any information in this report, it is recommendable to consult (without being limited to) one's financial, legal, tax, accounting, or regulatory advisor in any relevant jurisdiction.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. Each investor shall make his/her own appraisal of the tax and other financial merits of his/her investment.

## Sources

This report may be based on or contain information, such as opinions, estimates and valuations which emanate from: Nordea Markets' analysts or representatives, publicly available information, information from other units of Nordea, or other named sources.

To the extent this publication or report is based on or contain information emanating from other sources ("Other Sources") than Nordea Markets ("External Information"), Nordea Markets has deemed the Other Sources to be reliable but neither Nordea, others associated or affiliated with Nordea nor any other person, do guarantee the accuracy, adequacy or completeness of the External Information.

## Limitation of liability

Nordea or other associated and affiliated companies assume no liability as regards to any investment, divestment or retention decision taken by the investor on the basis of this report. In no event will Nordea or other associated and affiliated companies be liable for direct, indirect or incidental, special or consequential damages (regardless of whether being considered as foreseeable or not) resulting from the information in this report.

## Risk information

The risk of investing in certain financial instruments, including those mentioned in this report, is generally high, as their market value is exposed to a lot of different factors such as the operational and financial conditions of the relevant company, growth prospects, change in interest rates, the economic and political environment, foreign exchange rates, shifts in market sentiments etc. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. Past performance is not a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. When investing in individual shares, the investor may lose all or part of the investments.

## Conflicts of interest

Readers of this document should note that Nordea Markets has received remuneration from the company mentioned in this document for the production of the report. The remuneration is not dependent on the content of the report.

Nordea, affiliates or staff in Nordea, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the report.

To limit possible conflicts of interest and counter the abuse of inside knowledge, the analysts of Nordea Markets are subject to internal rules on sound ethical conduct, the management of inside information, handling of unpublished research material, contact with other units of Nordea and personal account dealing. The internal rules have been prepared in accordance with applicable legislation and relevant industry standards. The object of the internal rules is for example to ensure that no analyst will abuse or cause others to abuse confidential information. It is the policy of Nordea Markets that no link exists between revenues from capital markets activities and individual analyst remuneration. Nordea and the branches are members of national stockbrokers' associations in each of the countries in which Nordea has head offices. Internal rules have been developed in accordance with recommendations issued by the stockbrokers associations. This material has been prepared following the Nordea Conflict of Interest Policy, which may be viewed at [www.nordea.com/mifid](http://www.nordea.com/mifid).

## Distribution restrictions

The securities referred to in this report may not be eligible for sale in some jurisdictions. This report is not intended for, and must not be distributed to private customers in the UK or the US. This research report is intended only for, and may be distributed only to, accredited investors, expert investors or institutional investors in Singapore who may contact Nordea Bank, Singapore Branch of 138 Market Street, #09-01 CapitaGreen, Singapore 048946.

This publication or report may be distributed by Nordea Bank Abp Singapore Branch, which is subject to the supervision of the European Central Bank, the Finnish Financial Supervisory Authority and the Monetary Authority of Singapore.

This publication or report may be distributed in the UK to institutional investors by Nordea Bank Abp London Branch of 6th Floor, 5 Aldermanbury Square, London, EC2V 7AZ, which is under supervision of the European Central Bank, Finanssivalvonta (Financial Supervisory Authority) in Finland and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority in the United Kingdom. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available from us on request.

This report may not be mechanically duplicated, photocopied or otherwise reproduced, in full or in part, under applicable copyright laws.

**Analyst Shareholding**

Nordea Markets analysts do not hold shares in the companies that they cover. No holdings or other affiliations by analysts or associates.

**Fair value and sensitivity**

We calculate our fair values by weighting DCF, DDM, SOTP, asset-based and other standard valuation methods. Our fair values are sensitive to changes in valuation assumptions, of which growth, margins, tax rates, working capital ratios, investment-to-sales ratios and cost of capital are typically the most sensitive. It should be noted that our fair values would change by a disproportionate factor if changes are made to any or all valuation assumptions, owing to the non-linear nature of the standard valuation models applied (mentioned above). As a consequence of the standard valuation models we apply, changes of 1-2 percentage points in any single valuation assumption can change the derived fair value by as much as 30% or more. All research is produced on an ad hoc basis and will be updated when the circumstances require it.

**Marketing Material**

This research report should be considered marketing material, as it has been commissioned and paid for by the subject company, and has not been prepared in accordance with the regulations designed to promote the independence of investment research and it is not subject to any legal prohibition on dealing ahead of the dissemination of the report. However, Nordea Markets analysts are according to internal policies not allowed to hold shares in the companies/sectors that they cover.

**Market-making obligations and other significant financial interest**

Nordea Markets has no market-making obligations in Orexo.

**Investment banking transactions**

In view of Nordea's position in its markets readers should assume that the bank may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services to the company/companies

**Issuer Review**

*This report has not been reviewed by the Issuer prior to publication.*

**Completion Date**

29 Apr 2020, 02:33 CET

Nordea Bank Abp	Nordea Bank Abp, filial i Sverige	Nordea Danmark, Filial af Nordea Bank Abp, Finland	Nordea Bank Abp, filial i Norge
<b>Nordea Markets Division, Research</b> Visiting address: Aleksis Kiven katu 7, Helsinki FI-00020 Nordea Finland  Tel: +358 9 1651 Fax: +358 9 165 59710  Reg.no. 2858394-9 Satamaradankatu 5 Helsinki	<b>Nordea Markets Division, Research</b> Visiting address: Smålandsgatan 17 SE-105 71 Stockholm Sweden  Tel: +46 8 614 7000 Fax: +46 8 534 911 60	<b>Nordea Markets Division, Research</b> Visiting address: Grønjørdsvej 10 DK-2300 Copenhagen S Denmark  Tel: +45 3333 3333 Fax: +45 3333 1520	<b>Nordea Markets Division, Research</b> Visiting address: Essendropsgate 7 N-0107 Oslo Norway  Tel: +47 2248 5000 Fax: +47 2256 8650